Management Team
Our Management Team provides a wealth of knowledge and experience:
EXPERIENCE
272BIO Limited • Operations Director • Mar 2020 - present
Ixchelsis • Chief Operating Officer • Sep 2011 - present
Pfizer • Scientific Development Officer • Mar 2010 - Sep 2011
SPECIALITIES
Project, portfolio, program management; business, change, transformation and risk management; Pharmaceutical, Healthcare, Biotech, Research specialities.
PUBLICATIONS
2021
Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis SM Soond, LV Savvateeva, VA Makarov, NV Gorokhovets, PA Townsend, ...Pharmaceutics 13 (3), 339
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations MP Huynh-Le, CC Fan, R Karunamuni, WK Thompson, ME Martinez, ... Nature communications 12 (1), 1-9
High-Throughput Microbore Ultrahigh-Performance Liquid Chromatography-Ion Mobility-Enabled-Mass Spectrometry-Based Proteomics Methodology for the Exploratory Analysis of Serum …S Lennon, CJ Hughes, A Muazzam, PA Townsend, LA Gethings, ...Journal of Proteome Research
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer RA Karunamuni, MP Huynh-Le, CC Fan, W Thompson, RA Eeles, ...Prostate cancer and prostatic diseases, 1-10
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ...Nature genetics 53 (1), 65-75
Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis SM Soond, LV Savvateeva, VA Makarov, NV Gorokhovets, PA Townsend, ...Cancers 12 (11), 3476
Charles Owen
Allergy & Biotherapeutic Discovery Expert
charles.owen@272bio.com
T: +44 7748704654
EXPERIENCE
272BIO Limited • Operations Director • Mar 2020 - present
Ixchelsis • Chief Operating Officer • Sep 2011 - present
Pfizer • Scientific Development Officer • Mar 2010 - Sep 2011
SPECIALITIES
Project, portfolio, program management; business, change, transformation and risk management; Pharmaceutical, Healthcare, Biotech, Research specialities.
PUBLICATIONS
2021
Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis SM Soond, LV Savvateeva, VA Makarov, NV Gorokhovets, PA Townsend, ...Pharmaceutics 13 (3), 339
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations MP Huynh-Le, CC Fan, R Karunamuni, WK Thompson, ME Martinez, ... Nature communications 12 (1), 1-9
High-Throughput Microbore Ultrahigh-Performance Liquid Chromatography-Ion Mobility-Enabled-Mass Spectrometry-Based Proteomics Methodology for the Exploratory Analysis of Serum …S Lennon, CJ Hughes, A Muazzam, PA Townsend, LA Gethings, ...Journal of Proteome Research
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer RA Karunamuni, MP Huynh-Le, CC Fan, W Thompson, RA Eeles, ...Prostate cancer and prostatic diseases, 1-10
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ...Nature genetics 53 (1), 65-75
Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis SM Soond, LV Savvateeva, VA Makarov, NV Gorokhovets, PA Townsend, ...Cancers 12 (11), 3476
Liz Littlewood
Operations Director
Resourceful, experienced project and business management professional with a strong track record of delivering complex global projects and innovative business solutions.
A dedicated team leader with a proven history of excellent communication and people management.
Charles Owen
Allergy & Biotherapeutic Discovery Expert
Significant experience working in pharmaceutical and biotechnology industries, leading the consultancy. At Novartis, he was responsible for scientific support of omalizumab (Xolair), a therapeutic monoclonal antibody, which remains the only significant new therapeutic for the treatment of asthma launched in the last 40 years.
Charles Grummitt
Biotech Consultant
Personable and enthusiastic scientist with high-level biotechnology business and process development experience. Following a PhD at Cambridge I have spent several years in leading research institutions and biotechnology companies. I most recently headed up the co-development programme at a world-leading antibody discovery, engineering and production company.
Emma Campbell
Cell Biology, Pharmacology & Antibody Discovery Expert
Significant experience working in the pharma industry, and co-leads the consultancy. With a cell biology & pharmacology background, Emma has led a number of cross-functional teams responsible for target validation, biotherapeutic candidate screening, lead identification and preclinical development, in readiness for clinical Proof of Concept. Emma also has significant experience of supporting teams through PhI/II including compilation of preclinical Health Authority documentation.
Christine Labeur
Regulatory CMC
With a background in biochemistry, Christine has extensive CMC experience, working for and with various biotech and CDMO’s for both small and large molecules in management positions.
This includes 7 years as an Associate Director at Ablynx developing single chain recombinant antibodies for therapeutic use, where she built and managed the state of the art analytics teams (R&D and GMP QC Lab) that delivered several molecules ready for the clinic and market.
Our Management Team leverages their deep industry experience, data-driven insights and strategic innovation to empower our team of advocates who deliver novel healthcare solutions that help customers succeed in an increasingly challenging business climate.
